Application Note
Manufacturing of hiPSC-Derived Cardiomyocytes
Effective drug discovery and development relies on the availability of predictive preclinical model systems. Technologies based on human induced pluripotent stem cells (hiPSC) hold great promise to overcome this challenge.
In this application note researchers from Ncardia® show how they developed a bioprocess for the large-scale manufacturing of cardiomyocytes derived from a variety of healthy and diseased hiPSC lines for implementation into their DiscoverHIT platform.
